Acarix AB (publ) (FRA:7AC)

Germany flag Germany · Delayed Price · Currency is EUR
0.0162
0.00 (0.00%)
At close: Jun 5, 2026
Market Cap28.09M +27.2%
Revenue (ttm)734.18K +26.3%
Net Income-3.90M
EPS-0.00
Shares Out n/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Open0.0162
Previous Close0.0162
Day's Range0.0162 - 0.0162
52-Week Range0.0141 - 0.0448
Betan/a
Analystsn/a
Price Targetn/a
Earnings DateMay 18, 2026

About Acarix AB

Acarix AB (publ), a medical device company, develops solutions for rapid AI-based coronary artery disease rule-out. The company offers CADScor System, a point-of-care diagnostic aid that uses sensitive acoustics and advanced computational processing to support clinical decision making at the point of care. It sells its products in the Nordic countries, the United Kingdom, Germany, Switzerland, Austria, Mauritius, and the United States. The company was founded in 2009 and is headquartered in Malmö, Sweden. [Read more]

Industry Electromedical and Electrotherapeutic Apparatus
Founded 2009
Employees 8
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 7AC

Financial Performance

In 2025, Acarix AB's revenue was 7.36 million, an increase of 18.69% compared to the previous year's 6.20 million. Losses were -48.09 million, -27.34% less than in 2024.

Financial numbers in SEK Financial Statements

News

Acarix AB Earnings Call Transcript: Q1 2026

Revenue rose over 40% year-over-year, led by 90% U.S. growth on a constant currency basis, while gross margin held at 81% and operating costs fell 32%. Regulatory and reimbursement progress, strong clinical results, and expanding primary care adoption support a positive outlook.

19 days ago - Transcripts

Acarix AB Quarterly report: Q1 2026

Acarix AB has published its Q1 2026 quarterly earnings report on May 18, 2026.

19 days ago - Filings

Acarix AB Slides: Q1 2026

Acarix AB has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 18, 2026.

19 days ago - Filings

Acarix AB Earnings Call Transcript: Q4 2025

Q4 2025 saw 26% revenue growth, led by 87% U.S. market expansion and 64% increase in CADScor deliveries. Operating costs fell 23%, net loss improved 27%, and patch sales rose 73%. New payer and MDR certification support further global growth.

4 months ago - Transcripts

Acarix AB Quarterly report: Q4 2025

Acarix AB has published its Q4 2025 quarterly earnings report on February 12, 2026.

4 months ago - Filings

Acarix AB Slides: Q4 2025

Acarix AB has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 12, 2026.

4 months ago - Filings

Acarix AB Annual report: Q4 2025

Acarix AB has published its Q4 2025 annual report on February 12, 2026.

4 months ago - Filings

Acarix AB Earnings Call Transcript: Q3 2025

Q3 saw 137% global revenue growth, 95% increase in system deployments, and 49% reduction in net loss, driven by MENA expansion and robust U.S. performance. Gross margin remained strong at 85%, with expanding reimbursement and new clinical milestones.

7 months ago - Transcripts

Acarix AB Quarterly report: Q3 2025

Acarix AB has published its Q3 2025 quarterly earnings report on November 6, 2025.

7 months ago - Filings

Acarix AB Slides: Q3 2025

Acarix AB has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 6, 2025.

7 months ago - Filings

Acarix AB Earnings Call Transcript: Q2 2025

Q2 saw strong U.S. growth with a 27% increase in system deliveries and 53% patch sales growth in H1, while gross margin rose to 94% and operating costs fell 24%. Revenue declined due to European divestment, but new global distribution and reimbursement wins position the company for future profitability.

10 months ago - Transcripts

Acarix AB Quarterly report: Q2 2025

Acarix AB has published its Q2 2025 quarterly earnings report on August 21, 2025.

10 months ago - Filings

Acarix AB Slides: Q2 2025

Acarix AB has posted slides in relation to its Q2 2025 quarterly earnings report, which was published on August 21, 2025.

10 months ago - Filings

Acarix AB (publ) publishes Interim Report, April - June 2024

NEW YORK , Aug. 22, 2024 /PRNewswire/ -- Acarix, a leader in rapid AI and acoustics-based cardiac diagnostics, today reported its financial results for the second quarter of 2024. The company achieved...

1 year ago - PRNewsWire

Acarix Shares Begin Trading on the US-based OTCQB Market

NEW YORK , July 15, 2024 /PRNewswire/ -- Acarix, a leader in rapid AI and acoustics-based cardiac diagnostics, is pleased to announce that the Acarix shares (OTCQB: ACIXF) begin trading today on the O...

2 years ago - PRNewsWire